2020, Number 3
PDF size: 388.00 Kb.
ABSTRACTIntroduction. Influenza is a viral infection that affects the lower respiratory tract, having annual cycles. Oseltamivir has been one of the influenza antivirals on the World Health Organization (WHO) essential drugs list for a decade.
Objective. To determine the effectiveness and characteristics of adverse reactions in patients with influenza or influenza- like illness treated with oseltamivir.
Methods. Observational study with outpatient adult and adolescent patients under treatment with oseltamivir (75 mg every 12 hours), during the 2017-2018 winter season. Health status, functionality, quality of life, safety and satisfaction with medication were measured. The data were collected through booklets and telephone calls, delivered to the pharmacovigilance unit.
Results. 98 patients were included, 73.5% women, mean age 40 years. The median until improvement was fie days and for symptomatic relief it was seven days. The quality of life in the physical dimension improved on day seven. Global satisfaction with the treatment, average 84.1 and safety 94.4. 32 reported and resolved adverse reactions were detected, prevailing: nausea, dyspepsia, abdominal pain and dizziness.
Conclusion. Oseltamivir is effective as a treatment for influenza with a high level of satisfaction and presented some mild adverse reactions.
who, The selection and use of essential medicines. Report of the 21th who Expert Committee on Selection and Use of Essential Medicines, 2017 (including the 20th who Model List of Essential Medicines and the 6th who Model List of Essential Medicines for Children), unedited version, Ginebra, World Health Organization, 2017.
Gandek, B., Ware, J.E., Aaronson, N.K., Apolone, G., Bjorner, J.B., Brazier, J.E. et al., “Cross-validation of item selection and scoring for the sf-12 health survey in nine countries: results from the iqola Project. International Quality of Life Assessment”, J Clin Epidemiol, 1998, 51 (11): 1171-1178.